ReviewRheumatology international2025
Successful infliximab therapy in systemic sarcoidosis presenting with giant leg ulcers: a case based review.
Review in Rheumatology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ulcerative cutaneous sarcoidosis without systemic involvement: An isolated presentation.JAAD case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcoidosis is a chronic granulomatous inflammatory disease that primarily affects the lungs and skin. Cutaneous involvement occurs in approximately 30% of cases. We report herewith a rare case of a 55-year-old man with chronic, non-healing bilateral leg ulcers, ultimately diagnosed as ulcerative cutaneous sarcoidosis through histopathological confirmation. Giant leg ulcers complicating systemic sarcoidosis is rare and its management is challenging because there are no specific recommendation. In our case, a 24-month course of intravenous infliximab associated with oral prednisone induced sustained clinical remission. The current decline is three years. The aim of our work is to review the clinical presentation and management of ulcerative cutaneous sarcoidosis and compare them to reported cases in literature.
Indexed as
Identifiers
40327105What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.